Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Antineoplastons A10 and AS2-1 in Stage IV Kidney Cancer
NCT00003520Phase 2
Key facts
- Status
- Terminated
- Start
- Mar 1996
- Primary completion
- Jan 2005
- Countries
- 1
- Sponsor
- Burzynski Research Institute
- Modality
- Peptides, Small Molecules
- Conditions
- kidney cancer
01
Overview
Phase 2, open-label, single-arm trial of antineoplaston A10 and antineoplaston AS2-1 in kidney cancer, sponsored by Burzynski Research Institute. Primary endpoint: Objective Response to Therapy. Started Mar 1996; status: terminated.
02
Design
1 arm- Study design
- Non-randomizedOpen-label
Antineoplaston therapy
Atengenal + Astugenal IV infusions
03
Who it enrols
Adult patients with histologically confirmed Stage IV adenocarcinoma or transitional cell carcinoma of the kidney, measurable disease, and adequate organ function.
04
Endpoints
Primary
Objective Response to Therapy
Secondary
Safety and Tolerance of Antineoplaston Therapy
Beyond the preview
Go deeper on NCT00003520.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00003520.